Antiproliferation of cardamonin is involved in mTOR on aortic smooth muscle cells in high fructose-induced insulin resistance rats

European Journal of Pharmacology

Volumn 641, Issue 2-3, 2010, Pages 179-186

  Liao, Qin ^a   Shi, Dao Hua ^a   Zheng, Wei ^a   Xu, Xiang Jin ^a   Yu, Ying Hao ^a  

^a FUZHOU GENERAL HOSPITAL   (China)

Author keywords

(Rat); Cardamonin; Fructose; Insulin resistance; MTOR; Rapamycin; Vascular smooth muscle cell

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARDAMONIN; CREATININE; HERBACEOUS AGENT; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; UNCLASSIFIED DRUG; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG STRUCTURE; GENE OVEREXPRESSION; HYPERINSULINEMIA; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; THORACIC AORTA; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA, THORACIC; CARRIER PROTEINS; CELL PROLIFERATION; CHALCONES; DOSE-RESPONSE RELATIONSHIP, DRUG; FRUCTOSE; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MALE; MAMMALS; MOLECULAR STRUCTURE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RIBOSOMAL PROTEIN S6 KINASES; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 77954083279     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.05.024     Document Type: Article

References (43)

1. Ahmad S., Israf D.A., Lajis N.H., Shaari K., Mohamed H., Wahab A.A., Ariffin K.T., Hoo W.Y., Aziz N.A., Kadir A.A., Sulaiman M.R., Somchit M.N. Cardamonin, inhibits pro-inflammatory mediators in activated RAW 264.7 cells and whole blood. Eur. J. Pharmacol. 2006, 538:188-194.
2. Bheemasankara Rao C., Namosiva Rao T., Suryaprakasam S. Cardamonin and alpinetin from the seeds of Amomum subulatum. Planta Med. 1976, 29:391-392.
3. Chueh S.C., Kahan B.D. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis. Transplantation 2003, 76:375-382.
4. Corradetti M.N., Guan K.L. Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?. Oncogene 2006, 25:6347-6360.
5. Delbosc S., Paizanis E., Magous R., Araiz C., Dimo T., Cristol J.P., Cros G., Azay J. Involvement of oxidative stress and NADPH oxidase activation in the development of cardiovascular complications in a model of insulin resistance, the fructose-fed rat. Atherosclerosis 2005, 179:43-49.
6. Doug H., Chen S.X., Xu H.X., Kadota S., Namba T. A new antiplatelet diarylheptanoid from Alpinia blepharocalyx. J. Nat. Prod. 1998, 61:142-144.
7. Fabian M.C., Lakey J.R., Rajotte R.V., Kneteman N.M. The efficacy and toxicity of rapamycin in murine islet transplantation. In vitro and in vivo studies. Transplantation 1993, 56:1137-1142.
8. Giani J.F., Mayer M.A., Munoz M.C., Silberman E.A., Hocht C., Taira C.A., Gironacci M.M., Turyn D., Dominici F.P. Chronic infusion of angiotensin-(1-7) improves insulin resistance and hypertension induced by a high-fructose diet in rats. Am. J. Physiol. 2009, 296:E262-E271.
9. Hatziieremia S., Gray A.I., Ferro V.A., Paul A., Plevin R. The effects of cardamonin on lipopolysaccharide-induced inflammatory protein production and MAP Kinase and NFkappaB signalling pathways in monocytes/macrophages. Br. J. Pharmacol. 2006, 149:188-198.
10. Havrdova T., Saudek F., Boucek P., Adamec M., Koznarova R., Jedinakova T., Karasova L., Skibova J. Metabolic effect of sirolimus versus mycophenolate mofetil on pancreatic graft function in the early posttransplant period. Transpl. Proc. 2005, 37:3544-3545.
11. He W., Li Y., Liu J., Hu Z., Chen X. Specific interaction of chalcone-protein: cardamonin binding site II on the human serum albumin molecule. Biopolymers 2005, 79:48-57.
12. Hsueh W.A., Law R.E. Insulin signaling in the arterial wall. Am. J. Cardiol. 1999, 84:21J-24J.
13. Huang Y., Yao X.Q., Tsang S.Y., Lau C.W., Chen Z.Y. Role of endothelium/nitric oxide in vascular response to flavonoids and epicatechin. Acta Pharmacol. Sin. 2000, 21:1119-1124.
14. Israf D.A., Khaizurin T.A., Syahida A., Lajis N.H., Khozirah S. Cardamonin inhibits COX and iNOS expression via inhibition of p65NF-kappaB nuclear translocation and Ikappa-B phosphorylation in RAW 264.7 macrophage cells. Mol. Immunol. 2007, 44:673-679.
15. Jantan I., Raweh S.M., Sirat H.M., Jamil S., Mohd Yasin Y.H., Jalil J., Jamal J.A. Inhibitory effect of compounds from Zingiberaceae species on human platelet aggregation. Phytomedicine 2008, 15:306-309.
16. Josep M.C. Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors. Transpl. Rev. 2008, 22:73-81.
17. Kang D.G., Sohn E.J., Lee A.S., Kim J.S., Lee D.H., Lee H.S. Methanol extract of Sorbus commixta cortex prevents vascular inflammation in rats with a high fructose-induced metabolic syndrome. Am. J. Chin. Med. 2007, 35:265-277.
18. Krebs M., Brunmair B., Brehm A., Artwohl M., Szendroedi J., Nowotny P., Roth E., Furnsinn C., Promintzer M., Anderwald C., Bischof M., Roden M. The mammalian target of rapamycin pathway regulates nutrient-sensitive glucose uptake in man. Diabetes 2007, 56:1600-1607.
19. Lee C.H., Inoki K., Guan K.L. mTOR pathway as a target in tissue hypertrophy. Ann. Rev. Pharmacol. Toxicol. 2007, 47:443-467.
20. Lee J.H., Jung H.S., Giang P.M., Jin X., Lee S., Son P.T., Lee D., Hong Y.S., Lee K., Lee J.J. Blockade of nuclear factor-kappaB signaling pathway and anti-inflammatory activity of cardamomin, a chalcone analog from Alpinia conchigera. J. Pharmacol. Exp. Ther. 2006, 316:271-278.
21. Li G., Hu Y., Yang W., Jiang Y., Wang J., Xiao J., Hu Z., Pan X., Howard B.V., Bennett P.H. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the DA Qing IGT and diabetes study. Diab. Res. Clin. Pract. 2002, 58:193-200.
22. Lin Y.M., Zhou Y., Flavin M.T., Zhou L.M., Nie W., Chen F.C. Chalcones and flavonoids as anti-tuberculosis agents. Bioorg. Med. Chem. 2002, 10:2795-2802.
23. Lithell H.O. Hyperinsulinemia, insulin resistance, and the treatment of hypertension. Am. J. Hypertens. 1996, 9:150S-154S.
24. LoPiccolo J., Blumenthal G.M., Bernstein W.B., Dennis P.A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Update. 2008, 11:32-50.
25. Marx S.O., Jayaraman T., Go L.O., Marks A.R. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ. Res. 1995, 76:412-417.
26. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
27. Mayer M.A., Hocht C., Gironacci M., Opezzo J.A., Taira C.A., Fernandez B.E., Puyo A.M. Hypothalamic angiotensinergic-noradrenergic systems interaction in fructose induced hypertension. Regul. Peptides 2008, 146:38-45.
28. Mendes Sdos S., Candi A., Vansteenbrugge M., Pignon M.R., Bult H., Boudjeltia K.Z., Munaut C., Raes M. Microarray analyses of the effects of NF-kappaB or PI3K pathway inhibitors on the LPS-induced gene expression profile in RAW264.7 cells: synergistic effects of rapamycin on LPS-induced MMP9-overexpression. Cell. Signal. 2009, 21:1109-1122.
29. Miatello R., Risler N., Gonzalez S., Castro C., Ruttler M., Cruzado M. Effects of enalapril on the vascular wall in an experimental model of syndrome X. Am. J. Hypertens. 2002, 15:872-878.
30. Puyo A.M., Mayer M.A., Cavallero S., Donoso A.S., Peredo H.A. Fructose overload modifies vascular morphology and prostaglandin production in rats. Auton. Autacoid Pharmacol. 2004, 24:29-35.
31. Rahman S., Rahman T., Ismail A.A., Rashid A.R. Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis. Diab. Obes. Metab. 2007, 9:767-780.
32. Robbez Masson V., Lucas A., Gueugneau A.M., Macaire J.P., Paul J.L., Grynberg A., Rousseau D. Long-chain (n-3) polyunsaturated fatty acids prevent metabolic and vascular disorders in fructose-fed rats. J. Nutr. 2008, 138:1915-1922.
33. Sanchez-Lozada L.G., Tapia E., Jimenez A., Bautista P., Cristobal M., Nepomuceno T., Soto V., Avila-Casado C., Nakagawa T., Johnson R.J., Herrera-Acosta J., Franco M. Fructose-induced metabolic syndrome is associated with glomerular hypertension and renal microvascular damage in rats. Am. J. Physiol. Renal Physiol. 2007, 292:F423-F429.
34. Scott P.H., Brunn G.J., Kohn A.D., Roth R.A., Lawrence J.C. Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:7772-7777.
35. Shi D., Liao Q., Guo L., Lin Q. Improvement on the extraction process of cardamonin in Alpinia katsumadai. Yi Yao Dao Bao 2009, 28(8):1068-1069.
36. Soulard A., Hall M.N. SnapShot: mTOR signaling. Cell 2007, 129:434.
37. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br. Med. J. 1998, 17:703-713.
38. Vander Haar E., Lee S.I., Bandhakavi S., Griffin T.J., Kim D.H. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat. Cell Biol. 2007, 9:316-323.
39. Veroux M., Corona D., Giuffrida G., Gagliano M., Sorbello M., Virgilio C., Tallarita T., Zerbo D., Giaquinta A., Fiamingo P., Macarone M., Li Volti G., Caglia P., Veroux P. New-onset diabetes mellitus after kidney transplantation: the role of immunosuppression. Transpl. Proc. 2008, 40:1885-1887.
40. Veverka V., Crabbe T., Bird I., Lennie G., Muskett F.W., Taylor R.J., Carr M.D. Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR. Oncogene 2008, 27:585-595.
41. Wang Z.T., Lau C.W., Chan F.L., Yao X., Chen Z.Y., He Z.D., Huang Y. Vasorelaxant effects of cardamonin and alpinetin from Alpinia henryi K. Schum. J. Cardiovasc. Pharmacol. 2001, 37:596-606.
42. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
43. Yang X., Yang C., Farberman A., Rideout T.C., de Lange C.F., France J., Fan M.Z. The mTOR-signaling pathway in regulating metabolism and growth. J. Anim. Sci. 2008, 86:E36-E50.